Demonstrating the Value of Specialty Inflammatory Medications

Inflammatory medications are one of the top drivers of specialty drug spend. While these costly drugs can provide...

Read More

The First Step in Specialty Drug Management: Pipeline Monitoring and Review

The pipeline of new drugs coming to market continues to be steady, with 50 novel drugs approved by the FDA in 2021.[1] ...

Read More

Five Pipeline Developments to Watch in 2022

From continuing revolutionary advancements in gene therapy to the ongoing effects of the COVID-19 pandemic and the...

Read More

Making a Difference Every Day: A Focus on the Member Experience

The member experience is key for Elixir. This means more than a simple letter or access to a member portal. We strive...

Read More

Biosimilar Basics: Understanding the Difference Between Generics and Biosimilars

With rising drug costs, we’re all looking for ways to reduce out-of-pocket spend without sacrificing quality. Generic...

Read More

Elixir Formulary Decisions Deliver on Member Whole-Being Health

Prescription drug spend represented 13.7% of national health expenditures in 2018, totaling $500 billion, and is...

Read More

Closing One Chapter and Starting the Next: CMS' New Portal

The 2021 audit cycle is coming to a close. The Centers for Medicare and Medicaid Services (CMS) issued its last...

Read More

News on Approval of the First Interchangeable Biosimilar Insulin and More

From development of a medication for treatment-resistant HIV with a novel mechanism of action to approval of Pfizer's...

Read More

Changes in the Stars: The Pandemic's Impact on Star Ratings

The pandemic continues to have a profound impact on healthcare and that includes the Centers for Medicare and Medicaid...

Read More